432 related articles for article (PubMed ID: 29644524)
1. Discontinuation of antiviral prophylaxis increased the risk of hepatitis B virus reactivation in glomerulonephritis patients under immunotherapy: a real-life observation.
Fang J; Li W; Tan M; Chen W; Zhang C; Wang W; Xu Q; Guo X
Int Urol Nephrol; 2018 Sep; 50(9):1653-1660. PubMed ID: 29644524
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysis.
Fang J; Li W; Peng X; Tan Z; Tan M; Zhang C; Wang W; Xu Z; Zhou G
Int Urol Nephrol; 2017 Mar; 49(3):475-482. PubMed ID: 28032257
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
4. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.
Marrone A; Capoluongo N; D'Amore C; Pisaturo M; Esposito M; Guastafierro S; Siniscalchi I; Macera M; Boemio A; Onorato L; Rinaldi L; Minichini C; Adinolfi LE; Sagnelli E; Mastrullo L; Coppola N
J Viral Hepat; 2018 Feb; 25(2):198-204. PubMed ID: 29029365
[TBL] [Abstract][Full Text] [Related]
5. Overuse of prophylaxis in HBsAg and/or anti-HBc positive patients after increasing awareness to prevent reactivation in patients receiving immunosuppressive therapies: How rational are our prophylaxis decisions according to the literature?
Yenilmez E; Cetinkaya RA
Infez Med; 2019 Sep; 27(3):299-307. PubMed ID: 31545774
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
[TBL] [Abstract][Full Text] [Related]
8. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.
Yoo JJ; Cho EJ; Cho YY; Lee M; Lee DH; Cho Y; Lee JH; Yu SJ; Yoon SS; Yoon JH; Kim YJ
Liver Int; 2015 Dec; 35(12):2530-6. PubMed ID: 26053357
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
[TBL] [Abstract][Full Text] [Related]
11. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
Cho JH; Lim JH; Park GY; Kim JS; Kang YJ; Kwon O; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
Transpl Infect Dis; 2014 Apr; 16(2):295-303. PubMed ID: 24628837
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
[TBL] [Abstract][Full Text] [Related]
13. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy.
Rodríguez-Tajes S; Miralpeix A; Costa J; López-Suñé E; Laguno M; Pocurull A; Lens S; Mariño Z; Forns X
J Viral Hepat; 2021 Jan; 28(1):89-94. PubMed ID: 32969557
[TBL] [Abstract][Full Text] [Related]
14. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan.
Chen CY; Tien FM; Cheng A; Huang SY; Chou WC; Yao M; Tang JL; Tien HF; Sheng WH
BMC Gastroenterol; 2018 Jan; 18(1):6. PubMed ID: 29310589
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
[TBL] [Abstract][Full Text] [Related]
18. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Chen FW; Coyle L; Jones BE; Pattullo V
Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
[TBL] [Abstract][Full Text] [Related]
19. Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma.
Loglio A; Viganò M; Grossi G; Labanca S; Goldaniga M; Pompa A; Farina L; Rumi M; Corradini P; Facchetti F; Lunghi G; Baldini L; Lampertico P
Dig Liver Dis; 2019 Mar; 51(3):419-424. PubMed ID: 30316785
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.
Zhang X; Zhou Y; Chen C; Fang W; Cai X; Zhang X; Zhao M; Zhang B; Jiang W; Lin Z; Ma Y; Yang Y; Huang Y; Zhao H; Xu R; Hong S; Zhang L
J Immunother Cancer; 2019 Nov; 7(1):322. PubMed ID: 31753012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
